๐ข ๐๐๐๐ ๐๐: Novo Nordisk to Seek China Approval for Oral Wegovy Within Months - $่ฏบๅ่ฏบๅพทๅ ฌๅธ(NVO.US) $็คผๆฅ(LLY.US) $Hims & Hers Health(HIMS.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐จ๐ฏ๐จ ๐๐จ๐ซ๐๐ข๐ฌ๐ค plans to file for China approval of ๐จ๐ซ๐๐ฅ ๐๐๐ ๐จ๐ฏ๐ฒ within months.โค CEO Mike Doustdar announced the timeline during his first China visit as CEO.โค Oral weight-loss drugs target patients reluctant to use ๐ข๐ง๐ฃ๐๐๐ญ๐ข๐จ๐ง๐ฌ.โค Novo and ๐๐ฅ๐ข ๐๐ข๐ฅ๐ฅ๐ฒ are competing for China's obesity treatment market.โค Lilly submitted a China marketing application for ๐จ๐ซ๐๐จ๐ซ๐ ๐ฅ๐ข๐ฉ๐ซ๐จ๐ง in late 2025.โค China's semaglutide patent expired in ๐๐๐ซ๐๐ก; data protection lasts until early 2027.โค Novo expects ๐ ๐๐ง๐๐ซ๐ข๐ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐จ๐ง beginning in Q2 2027.โค Novo says large-scale manufacturing could be a key barrier for competitors.โค Oral Wegovy has secured approvals in the ๐.๐. and ๐.๐., with a U.S. launch underway.โค China GLP-1 sales reached about ๐๐ฎ๐๐ง ๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ($207 million) in Q1.ๆฌๆ็ๆๅฝๅฑๅไฝ่ /ๆบๆๆๆใ
ๅฝๅๅ ๅฎนไป ไปฃ่กจไฝ่ ่ง็น๏ผไธๆฌๅนณๅฐ็ซๅบๆ ๅ ณใๅ ๅฎนไป ไพๆ่ต่ ๅ่๏ผไบฆไธๆๆไปปไฝๆ่ตๅปบ่ฎฎใๅฆๅฏนๆฌๅนณๅฐๆไพ็ๅ ๅฎนๆๅกๆไปปไฝ็้ฎๆๅปบ่ฎฎ๏ผ่ฏท่็ณปๆไปฌใ
ๅ่กจไฝ ็่ฏ่ฎบ
ๆๆ ่ฏ่ฎบ